Gen Surg Vivas · trauma
Exsanguinating polytrauma listed for damage control — abbreviation, ratios, clock, packs, closure
Fellowship viva on damage control surgery: triad-versus-diamond trap, ABC and predictor panel, PROPPR and EAST ratios, TXA windows, packing timing, stage-1 forbids, traction closure hierarchy, SLEEP-TIME clock, matched open-abdomen harm and ITACTIC.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
Examiner probes
- The candidate says the lethal diamond predicts death better than the triad. Correct them — with the cohort numbers — then state your calcium practice.[9][8][10]
- Score his transfusion need and his early-death risk at the bedside: ABC variables with test characteristics, plus the admission predictor panel with values.[12][13]
- Ratios and cryoprecipitate: what does PROPPR actually prove, what does EAST recommend with what odds ratios, and what did the 49,301-patient cryoprecipitate analysis add?[24][25][34]
- TXA: dose, the three time windows with effects, the 90-minute and 2-hour refinements, and who is under-treated.[26][27][28][29][31]
- At stage 1, what do you deliberately NOT do — for liver, for destructive colon, for vessels — and when do packs come out?[48][47][40][41]
- Closure clock and honesty: SLEEP-TIME numbers, the matched harm of the unnecessary open abdomen, and the ITACTIC answer to viscoelastic believers.[50][65][33]
Model responses
1. Diamond hypothesised, triad undefeated. Calcium touches every triad limb, motivating the diamond — but 2141 transfused severe-trauma patients (median ISS 27) gave diamond AUC 0.71 versus triad 0.72 (p equals 0.26): no incremental prediction.[9][8] Practice: monitor ionised calcium (hypocalcaemia below 1.1), replace per protocol — half of prehospital patients are already low at 51 percent — but never protocolise empiric prehospital calcium before transfusion.[10]
2. ABC 4; six-predictor panel. Penetrating mechanism, positive FAST, systolic 82, heart rate 135 — all four ABC variables; threshold 2 or more gives 75 percent sensitivity and 86 percent specificity for massive transfusion.[12] Early-death predictors: INR above 1.2, base deficit above 3, head AIS 3 or more, temperature below 35, lactate above 6, haemoglobin below 7 — from 319 damage-control patients with 16.3 percent early death and lactate 5.81 versus 3.46 separating the dead from the survivors.[13]
3. Haemostasis yes, mortality unproven; ratios recommended; cryo helps early. PROPPR 1:1:1 versus 1:1:2: mortality null at 24 hours and 30 days, exsanguination 9.2 versus 14.6 percent, haemostasis 86 versus 78 percent, no complication excess.[24] EAST: run a protocol (OR 0.61), target high plasma (OR 0.60) and platelet (OR 0.44) ratios with empiric equal amounts, conditional early TXA.[25] High cryoprecipitate ratios after the 2019 guideline change: adjusted OR 0.52 at 6 hours and 0.74 at 24 hours across 49,301 patients.[34]
4. 1 g plus 1 g; ≤1 h RR 0.68, 1–3 h RR 0.79, >3 h RR 1.44 harm; refined to 90 minutes–2 h. CRASH-2 regimen and effects as above; PATCH analysis finds benefit only within 90 minutes (adjusted RR 0.64 versus 1.04 beyond); causal forest optimal rule is within 2 hours or GCS below 9.[26][27][28][29] Women benefit equally (RR 0.69 versus 0.80) but receive TXA far less (OR 0.39) — check your own bay's equity.[31]
5. Pack, staple, divert — never definitively repair. No destructive-colon anastomosis at stage 1 (25 percent leak at delay, leak kills; diversion equivalent); no major anatomic resection or atriocaval shunt (redundant — packing, suture, debridement and radiology replaced them); packs out at 36 to 72 hours with first look after 48 (21 versus 4 percent rebleed early).[48][47][40][41]
6. Close early, open only with indication, test viscoelastics honestly. SLEEP-TIME: 92.9 percent closure, first takeback within 24 hours, minus 91.5 percent odds per extra laparotomy.[50] Matched peritonitis harm of unnecessary open abdomen: 71.2 versus 41.4 percent complications, 22.5 versus 11.7 percent death.[65] ITACTIC: viscoelastic-augmented versus conventional protocols identical (67 versus 64 percent transfusion-free at 24 hours; death 25 versus 28) — claim no superiority.[33]
References20ShowHide
- [8]Wray JP, Bridwell RE, Schauer SG, et al. The diamond of death: Hypocalcemia in trauma and resuscitation. Am J Emerg Med, 2021.PMID 33421674
- [9]Dupuy C, Martinez T, Duranteau O, et al. Comparison of the lethal triad and the lethal diamond in severe trauma patients: a multicenter cohort. World J Emerg Surg, 2025.PMID 39773274
- [10]Brandt MD, Liccardi C, Heidle J, et al. Prevalence of Trauma-Induced Hypocalcemia in the Prehospital Setting. J Spec Oper Med, 2023.PMID 37094288
- [12]Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma, 2009.PMID 19204506
- [13]Frischknecht A, Lustenberger T, Bukur M, et al. Damage control in severely injured trauma patients - A ten-year experience. J Emerg Trauma Shock, 2011.PMID 22090736
- [24]Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 2015.PMID 25647203
- [25]Cannon JW, Khan MA, Raja AS, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg, 2017.PMID 28225743
- [26]Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010.PMID 20554319
- [27]Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, 2011.PMID 21439633
- [28]Ali A, Gruen RL, Bernard SA, et al. Tranexamic Acid Timing and Mortality Impact After Trauma. Ann Emerg Med, 2026.PMID 40751727
- [29]Osawa I, Goto T, Roberts I Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg, 2025.PMID 40277024
- [31]Nutbeam T, Roberts I, Weekes L, et al. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data. Br J Anaesth, 2022.PMID 35597623
- [33]Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med, 2021.PMID 33048195
- [34]Hynes AM, Cannon JW, Yan R, et al. Do not forget the cryoprecipitate: The impact of the 2019 Joint Trauma System Damage Control Resuscitation Clinical Practice Guideline on mortality. J Trauma Acute Care Surg, 2026.PMID 41589734
- [40]Nicol AJ, Hommes M, Primrose R, et al. Packing for control of hemorrhage in major liver trauma. World J Surg, 2007.PMID 17334868
- [41]Caruso DM, Battistella FD, Owings JT, et al. Perihepatic packing of major liver injuries: complications and mortality. Arch Surg, 1999.PMID 10487590
- [47]Badger SA, Barclay R, Campbell P, et al. Management of liver trauma. World J Surg, 2009.PMID 19760312
- [48]Oosthuizen G, Buitendag J, Variawa S, et al. Penetrating colonic trauma and damage control surgery: Anastomosis or stoma? ANZ J Surg, 2021.PMID 34056835
- [50]Kwon E, Krause C, Luo-Owen X, et al. Time is domain: factors affecting primary fascial closure after trauma and non-trauma damage control laparotomy (data from the EAST SLEEP-TIME multicenter registry). Eur J Trauma Emerg Surg, 2022.PMID 34845499
- [65]Kao AM, Cetrulo LN, Baimas-George MR, et al. Outcomes of open abdomen versus primary closure following emergent laparotomy for suspected secondary peritonitis: A propensity-matched analysis. J Trauma Acute Care Surg, 2019.PMID 31045736